Developing potent and safe cytotoxins to reduce severe side-effects
28 Apr 2026
ADC Cytotoxic Payload
- How can we effectively identify the optimal payload–linker combinations to enhance the efficacy and safety of antibody-drug conjugates (ADCs)?
- What strategies can be employed to address and mitigate lung toxicity associated with topoisomerase inhibitor payloads in ADCs?
- How can we manage and reduce the excessive toxicity caused by DNA-alkylating payloads in ADC therapeutics?
- What approaches are needed to mitigate toxicity concerns related to novel payload classes, particularly targeted protein degraders such as PROTAC-based payloads?
- Are dual-payload ADCs a genuine therapeutic advancement, or do they represent overhyped complexity in the development of next-generation ADCs?
Industry Expert
